Indeed, using a mouse xenograft model, the authors observed that this mutation enhances melanoma growth and invasion and confers drug resistance against BRAF and MEK kinase inhibitors (Revach et al., 2016; Mohan et al., 2019) (Table 1). Here, MAP2K7 is linked to melanoma.